Vanda Pharmaceuticals, Inc. (VNDA) Posts Wider than Expected Q3 Loss
Tweet
Share
E-mailGet Alerts VNDA Hot Sheet
Price: $5.44 +3.42%
Financial Fact:
Net income (loss): -430K
Today's EPS Names:
SCWO, HSAI, SYRS, More
Financial Fact:
Net income (loss): -430K
Today's EPS Names:
SCWO, HSAI, SYRS, More
Join SI Premium – FREE
Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) reported Q3 EPS of ($0.11), $0.03 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $8 million versus the consensus estimate of $8.26 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- This biotech stock offers a buying opportunity: B. Riley
- Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
- La-Z-Boy (LZB) Misses Q1 EPS by 6c, Misses on Revenue; Offers Weak Q2 Revenue Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
